Decision-making in a phase II clinical trial: A new approach combining Bayesian and frequentist concepts

Pharmaceutical Statistics

Volumn 4, Issue 2, 2005, Pages 119-128

  Stallard, Nigel ^a   Whitehead, John ^a   Cleall, Simon ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Bayesian sequential design; Clinical trial monitoring; Decision rules; Predictive probability

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PLACEBO;

ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DECISION MAKING; DRUG EFFICACY; DRUG RESPONSE; HUMAN; METASTASIS; PREDICTION; PROBABILITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE;

EID: 21244466674     PISSN: 15391604     EISSN: None     Source Type: Journal    
DOI: 10.1002/pst.164     Document Type: Article

References (14)

1. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994; 50: 337-349.
2. Pocock SJ. Clinical trials: a practical approach. Wiley: New York, 1983.
3. Senn S. Statistical issues in drug development. Wiley: New York, 1997.
4. Whitehead J. The design and analysis of sequential clinical trials. Wiley: New York, 1997.
5. Scharfstein DO, Tsiatis AA, Robins JM. Semiparametric efficiency and its implication on the design and analysis of group sequential studies. Journal of the American Statistical Association 1997; 92:1342-1350.
6. Stallard N. Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 1998; 54:279-294.
7. Ravlin PM, Burris HA, Cook G et al. Phase II trial of docetaxel: advanced antrhacycline-resistant or antracenedione-resistant breast cancer. Journal of Clinical Oncology 1995; 13:2879-2885.
8. Burris HA. Single-agent docetaxel (Taxotere) in randomized phase III trials. Seminars in Oncology 1999; 26(3 Suppl 9):1-6.
9. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society, Series A 1994; 157:357-416.
10. Novick MR, Grizzle JE. A Bayesian approach to the analysis of data from clinical trials. Journal of the American Statistical Association 1965; 60: 81-96.
11. Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomised phase II trial to phase III. Biometrics 2002; 58:823-831.
12. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18: 1833-1848.
13. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703.
14. Berry DA, Ho C-H. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics 1988; 44:219-227.